Results 161 to 170 of about 52,122 (312)

Nociceptin/orphanin FQ and motor activity: behavioural, biochemical and electrophysiological studies in models of Parkinson’s disease

, 2010
Nociceptin/orphanin FQ (N/OFQ) is an opioid-like neuropeptide which activates the NOP receptor. N/OFQ exerts an inhibitory control on locomotion through inhibition of dopamine (DA) neurons located in the substantia nigra (SN), which degenerate in ...
Viaro, Riccardo
core  

Multivalent antibody‐based conjugates as new tools for tailored modulation of G protein–coupled receptors

British Journal of Pharmacology, EarlyView.
The G protein–coupled receptor (GPCR) superfamily consists of the most common targets of approved drugs. Targeting GPCRs offers appealing avenues for therapeutic development. Antibodies and their fragments, such as single‐domain antibodies (VHHs or nanobodies), have emerged as useful alternatives to small molecule pharmacophores as building blocks in ...
Shivani Sachdev, Ross W. Cheloha
wiley   +1 more source

In silico prediction of novel effective combinational treatment of chronic pain in individual patients: A joint white paper of the H2020 QSPainRelief consortium

British Journal of Pharmacology, EarlyView.
Abstract Opioids are prescribed widely for chronic pain despite well‐recognised risks and variable long‐term benefit, reflecting the lack of effective alternatives for many patients. Combination therapies offer a promising strategy to enhance efficacy whilst reducing side effects.
André Mouraux, Solenn Gousset, Beltrán Alvarez, Monica Baiula, Wouter Bakker, Andrea Bedini, Monir Bertayli, Divakar Budda, Robert Carr, Elisabetta Cuna, Óscar Díaz, Nina Donner, Jesús Giraldo, Geert‐Jan Groeneveld, Berfin Gülave, David Guydan, Hemme Hijma, Rafael Maldonado, Pedro Renault, Carlos Rinaudo, Jeroen Elaissaiss‐Schaap, Athan Spiros, Sara Stoeber, Petri Takkala, Daan van Valkengoed, Coen van Hasselt, Elizabeth (Liesbeth) CM de Lange   +26 more
wiley   +1 more source

The Hepatitis C Cascade of Care for Opioid Agonist Therapy Recipients in Australia. [PDF]

Clin Infect Dis
Griffin S, Asselin J, Wilkinson AL, Traeger MW, Pedrana A, Winter RJ, Thompson AJ, Penn M, Dimech W, Donovan B, Hellard M, Stoové M.   +11 more
europepmc   +1 more source

Novel Histopathologic Features of Diffuse Blue‐Gray Hyperpigmentation Associated With Kratom Use: A Case Report and Literature Review

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Background Drug‐induced hyperpigmentation accounts for 10%–20% of acquired pigmentary disorders and can be misdiagnosed for other causes such as melasma, post inflammatory changes, or heavy metal deposition. Kratom (Mitragyna speciosa), a Southeast Asian plant with an opioid‐like profile, has been increasingly used in the United States for ...
Rita Kamoua, Kristen Paradine, Craig A. Rohan, Mary McDaniel, Diane Perkins   +4 more
wiley   +1 more source

Association between thyroidea function and opioid agonist therapy: a prospective cohort study from Norway. [PDF]

J Endocr Soc
Heldal AT, Vold JH, Viste K, Chalabianloo F, Mellgren G, Johansson KA, Fadnes LT.   +6 more
europepmc   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Major Adverse Liver Outcomes in People With Type 2 Diabetes and Metabolic Dysfunction‐Associated Steatotic Liver Disease

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Treatment options for metabolic dysfunction‐associated steatotic liver disease (MASLD) are limited. While glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors improve cardiovascular outcomes, comparative effectiveness on liver‐related outcomes remains unclear.
Gregor A. Maier, Ramon A. Hofmann, Michael Roden, Wolfgang Rathmann, Oliver Kuss   +4 more
wiley   +1 more source

Policy changes in opioid agonist therapy and impacts on HIV and hepatitis C prevention in Canadian federal prisons. [PDF]

Lancet Reg Health Am
Kronfli N, Madden LM, Stoové M, Price O, Altice FL.   +4 more
europepmc   +1 more source

Analgesic effects of alpha‐2‐adrenoreceptor agonists in equine medicine: systemic, spinal, and local applications

Equine Veterinary Education, EarlyView.
Summary Alpha‐2‐adrenoreceptor agonists provide analgesia when used as sole agents but can also be used in combination with other drugs for their additive and potentially synergistic effects. Further, because of their effects on blood flow, alpha‐2‐adrenoreceptor agonists act to extend and perhaps intensify the effects of drugs, such as local ...
J. Brandly, J. R. Page, J. A. E. Hubbell, W. W. Muir III, K. Hopster   +4 more
wiley   +1 more source

Factors influencing family physicians' willingness to prescribe opioid agonist therapy using virtual modalities: a qualitative analysis. [PDF]

Front Med (Lausanne)
Muñoz-Violant S, Spencer S, Gooderham E, Narayan S, Nosyk B, McCracken RK, Hedden L.   +6 more
europepmc   +1 more source